Get the Stockscreener App
2.065
0.98%
0.025
Inflarx Nv stock is traded at $2.065, with a volume of 323.53K.
It is up +0.98% in the last 24 hours and up +11.05% over the past month.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$2.04
Open:
$2.04
24h Volume:
323.53K
Relative Volume:
0.27
Market Cap:
$304.05M
Revenue:
$72,500
Net Income/Loss:
$-45.96M
P/E Ratio:
-3.0305
EPS:
-0.6814
Net Cash Flow:
$-44.56M
1W Performance:
+5.10%
1M Performance:
+11.05%
6M Performance:
+142.55%
1Y Performance:
+138.73%
1-Day Range:
$2.03
$2.09
1-Week Range:
$1.92
$2.09
52-Week Range:
$0.7984
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
2.0632 | 300.63M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.54 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.82 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.68 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.27 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx Nv Stock (IFRX) Latest News
InflaRx (IFRX) investors report 15.6% and 12.5% stakes in updated 13G/A - Stock Titan
Sirenia Capital (IFRX) discloses 8.9M InflaRx shares, a 6.1% ownership stake - Stock Titan
InflaRx (IFRX): Farallon group reports 3.33M-share, 2.3% beneficial stake - Stock Titan
EDGAR Filing Documents for 0001140361-26-033149 - SEC.gov
InflaRx N.V. SEC Filing (Aug 13, 2026) - Stock Titan
InflaRx (IFRX) Short Interest & Short Float | Updated Aug 2026 $IFRX - MarketBeat
HC Wainwright Estimates InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - marketbeat.com
Cantor Fitzgerald Increases InflaRx (NASDAQ:IFRX) Price Target to $6.00 - MarketBeat
InflaRx N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC and Abigail Johnson (IFRX) disclose 5.5% Inflarx stake in Schedule 13G - Stock Titan
InflaRx NV reports results for the quarter ended June 30Earnings Summary - TradingView
InflaRx N.V. (IFRX) sets up $250M shelf for stock, debt and warrants - Stock Titan
IFRX: Advanced pipeline in AAV and renal diseases, with strong funding and reduced net loss - TradingView
InflaRx Files Mid‑Year 2026 Unaudited Results in SEC Form 6‑K - TipRanks
InflaRx Q2 2026 earnings: Lower costs narrow the operating loss - TradingKey
InflaRx (Nasdaq: IFRX) raises $140m, funds C5a pipeline into 2029 - Stock Titan
InflaRx Reports Q2 2026 Results and Business Update, Advances Izicopan in AAV and Renal Diseases - Quiver Quantitative
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones - Yahoo! Finance Canada
IFRX Q2'26 Earnings: EPS estimate is (0.07) USD - TradingView
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
InflaRx NV expected to post a loss of 6 cents a shareEarnings Preview - TradingView
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline - sharewise.com
InflaRx N.V. Revenue Breakdown – NASDAQ:IFRX - TradingView
No Conference Call Planned for InflaRx's Aug. 6 Results - stocktitan.net
IFRX Q2'26 Earnings: revenue estimate is 6.40K USD - TradingView
InflaRx (NASDAQ:IFRX) Upgraded by Zacks Research to "Strong-Buy" Rating - MarketBeat
InflaRx NV (IFRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InflaRx (NASDAQ:IFRX) Trading Down 2.3%Time to Sell? - MarketBeat
InflaRx NV (IFRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InflaRx NV (IFRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InflaRx N.V. Revenue Breakdown – SWB:IF0 - TradingView
InflaRx NV (IFRX) Institutional Confidence - TradingKey
IFRX|InflaRx NV|Price:1.740|Chg%:+0.010 - TradingKey
IFRX|InflaRx NV|Price:1.690|Chg%:-0.050 - TradingKey
TradingKey - TradingKey
InflaRx N.V. Revenue Breakdown – BOATS:IFRX - TradingView
InflaRx NV (IFRX) Cash Flow - TradingKey
InflaRx NV (IFRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InflaRx (IFRX) Under Pressure as Shares Slip 2.88% Toward Key SupportAlgorithmic Stock Picks - dars.gov.et
IFRX Stock Price, Quote & Chart - ChartMill
InflaRx N.V. (IFRX) Hovers Near Support After Marginal DeclineMA Cross Alert - dars.gov.et
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss on Stability, Stock EasesEarnings Call Q&A - DonanımHaber
InflaRx NV focus on immune therapies as investors weigh long-term prospects - ad-hoc-news.de
InflaRx N.V. (IFRX) Slips 1.79% as Stock Approaches Key Support LevelETF Premium Discount - DonanımHaber
IFRX Q1 2026 Earnings: Surprise EPS Beat Despite Pre-Revenue StatusCapex Guidance - dars.gov.et
Price to earnings forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
IFRXInflaRx NV Revenue Breakdown - Finviz
Price to book forward of InflaRx N.V. – NASDAQ:IFRX - TradingView
InflaRx Moves to Broaden AAV Strategy in Europe After EMA Setback for Tavneos - TipRanks
InflaRx (IFRX) rethinks European AAV path after EMA Tavneos setback - Stock Titan
Inflarx Nv Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):